Increased platelet activation and platelet-inflammasome engagement during chikungunya infection.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 01 06 2022
accepted: 11 08 2022
entrez: 3 10 2022
pubmed: 4 10 2022
medline: 5 10 2022
Statut: epublish

Résumé

Chikungunya fever is a viral disease transmitted by mosquitoes of the genus Aedes. The infection is usually symptomatic and most common symptoms are fever accompanied by joint pain and swelling. In most cases symptoms subside within a week. However, severe prolonged and disabling joint pain, that may persist for several months, even years, are reported. Although the pathogenesis of Chikungunya infection is not fully understood, the evolution to severe disease seems to be associated with the activation of immune mechanisms and the action of inflammatory mediators. Platelets are recognized as inflammatory cells with fundamental activities in the immune response, maintenance of vascular stability and pathogenicity of several inflammatory and infectious diseases. Although the involvement of platelets in the pathogenesis of viral diseases has gained attention in recent years, their activation in Chikungunya has not been explored. The aim of this study was to analyze platelet activation and the possible role of platelets in the amplification of the inflammatory response during Chikungunya infection. We prospectively included 132 patients attended at the Quinta D'Or hospital and 25 healthy volunteers during the 2016 epidemic in Rio de Janeiro, Brazil. We observed increased expression of CD62P on the surface of platelets, as well as increased plasma levels of CD62P and platelet-derived inflammatory mediators indicating that the Chikungunya infection leads to platelet activation. In addition, platelets from chikungunya patients exhibit increased expression of NLRP3, caspase 4, and cleaved IL-1β, suggestive of platelet-inflammasome engagement during chikungunya infection.

Identifiants

pubmed: 36189282
doi: 10.3389/fimmu.2022.958820
pmc: PMC9520464
doi:

Substances chimiques

Inflammasomes 0
Inflammation Mediators 0
NLR Family, Pyrin Domain-Containing 3 Protein 0
P-Selectin 0
Caspases EC 3.4.22.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

958820

Informations de copyright

Copyright © 2022 Gomes de Azevedo-Quintanilha, Campos, Teixeira Monteiro, Dantas do Nascimento, Calheiros, Oliveira, Dias, Soares, Santos, Tavares, Lopes Souza, Hottz, Bozza and Bozza.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Lancet Infect Dis. 2008 Jan;8(1):2-3
pubmed: 18156079
Lancet Infect Dis. 2007 May;7(5):319-27
pubmed: 17448935
J Infect Dis. 2011 Jul 1;204(1):115-23
pubmed: 21628665
Immunol Rev. 2015 Nov;268(1):241-52
pubmed: 26497525
Hypertension. 2001 Feb;37(2):334-8
pubmed: 11230294
PLoS Pathog. 2017 May 19;13(5):e1006385
pubmed: 28542641
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3564-73
pubmed: 26106157
J Leukoc Biol. 2020 Oct;108(4):1157-1182
pubmed: 32779243
J Thromb Haemost. 2015 Jun;13(6):893-908
pubmed: 25900780
Can J Microbiol. 1977 Sep;23(9):1237-44
pubmed: 561645
Science. 2012 Dec 7;338(6112):1348-51
pubmed: 23224555
Arthritis Rheumatol. 2014 Feb;66(2):319-26
pubmed: 24504804
J Exp Med. 2010 Feb 15;207(2):429-42
pubmed: 20123960
J Infect Dis. 1970 Dec;122(6):523-31
pubmed: 5530774
Physiol Rev. 2016 Oct;96(4):1211-59
pubmed: 27489307
J Infect Dis. 2012 Apr 15;205(8):1321-9
pubmed: 22383677
Front Immunol. 2019 Sep 13;10:2204
pubmed: 31572400
Semin Immunopathol. 2012 Jan;34(1):5-30
pubmed: 21818701
Virology. 2016 Jun;493:162-72
pubmed: 27058763
Sci Rep. 2018 Oct 9;8(1):14999
pubmed: 30301959
World J Virol. 2013 May 12;2(2):91-101
pubmed: 24175233
PLoS Pathog. 2008 Feb 8;4(2):e29
pubmed: 18282093
Cell. 2005 Aug 12;122(3):379-91
pubmed: 16096058
Nat Commun. 2020 Jun 24;11(1):3276
pubmed: 32581219
Front Cell Infect Microbiol. 2021 Aug 26;11:715208
pubmed: 34513730
PLoS One. 2007 Jun 13;2(6):e527
pubmed: 17565380
PLoS Negl Trop Dis. 2013;7(3):e2137
pubmed: 23556021
Nat Rev Rheumatol. 2012 Sep;8(9):534-42
pubmed: 22868927
J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Aug 1;964:26-40
pubmed: 24685839
J Leukoc Biol. 2020 Oct;108(4):1293-1306
pubmed: 32663907
JAMA. 2021 Jul 27;326(4):332-338
pubmed: 34213527
J Immunol. 2020 Jun 15;204(12):3063-3069
pubmed: 32513874
Travel Med Infect Dis. 2017 Jan - Feb;15:8-22
pubmed: 28163198
J Thromb Haemost. 2011 Jun;9(6):1097-107
pubmed: 21435167
Viruses. 2014 Nov 24;6(11):4628-63
pubmed: 25421891
PLoS One. 2013 May 28;8(5):e63410
pubmed: 23723981
Infect Genet Evol. 2015 Jun;32:401-8
pubmed: 25847693
Front Immunol. 2020 Nov 27;11:585146
pubmed: 33329561
Curr Top Microbiol Immunol. 2022;435:55-80
pubmed: 30656438
Front Pharmacol. 2021 Jul 05;12:708665
pubmed: 34290613
J Thromb Haemost. 2013 May;11(5):951-62
pubmed: 23433144
Antiviral Res. 2017 Dec;148:32-42
pubmed: 29097227
Blood. 2020 Sep 10;136(11):1330-1341
pubmed: 32678428
PLoS Negl Trop Dis. 2019 Nov 25;13(11):e0007837
pubmed: 31765380
Cell Death Differ. 2015 Apr;22(4):526-39
pubmed: 25526085
Int J Med Sci. 2019 Mar 9;16(3):461-469
pubmed: 30911280
Int J Mol Med. 2018 Jun;41(6):3620-3628
pubmed: 29512688
Blood. 2020 Sep 10;136(11):1317-1329
pubmed: 32573711
Pathog Dis. 2016 Apr;74(3):
pubmed: 26657109
PLoS Negl Trop Dis. 2014 Jun 12;8(6):e2858
pubmed: 24921924
Nat Commun. 2019 Apr 16;10(1):1780
pubmed: 30992428
PLoS One. 2009;4(1):e4261
pubmed: 19156204
Nat Med. 2007 Apr;13(4):463-9
pubmed: 17384648
Vector Borne Zoonotic Dis. 2015 Apr;15(4):241-9
pubmed: 25897810
Exp Hematol. 2021 Dec;104:32-39
pubmed: 34563606
Sci Rep. 2019 Feb 26;9(1):2760
pubmed: 30809003
Blood. 2019 May 9;133(19):2013-2026
pubmed: 30723081
Front Immunol. 2021 Mar 12;12:634386
pubmed: 33777022
J Immunol. 2014 Aug 15;193(4):1864-72
pubmed: 25015827
Arthritis Rheumatol. 2019 Jul;71(7):1185-1190
pubmed: 30747500
Nat Rev Microbiol. 2006 Jun;4(6):445-57
pubmed: 16710325
Cell Host Microbe. 2008 Aug 14;4(2):179-87
pubmed: 18692777
PLoS Pathog. 2007 Jun;3(6):e89
pubmed: 17604450
Science. 2009 Feb 6;323(5915):797-800
pubmed: 19197068
J Immunol. 2009 Oct 1;183(7):4715-22
pubmed: 19752233
Am J Surg Pathol. 2021 May 1;45(5):587-603
pubmed: 33481385
Blood. 2013 Nov 14;122(20):3405-14
pubmed: 24009231
J Immunol. 2015 Jun 15;194(12):5579-87
pubmed: 26048965
Cell. 1989 Oct 20;59(2):305-12
pubmed: 2478294
Antiviral Res. 2013 Sep;99(3):345-70
pubmed: 23811281
Front Med (Lausanne). 2018 Apr 30;5:121
pubmed: 29761104
FEMS Immunol Med Microbiol. 2008 Jun;53(1):46-51
pubmed: 18371071
J Infect Dis. 2011 Jan 15;203(2):149-57
pubmed: 21288813
Blood Adv. 2022 Sep 13;6(17):5085-5099
pubmed: 35420680
Front Immunol. 2019 Jul 17;10:1687
pubmed: 31379873
J Am Heart Assoc. 2020 Sep 15;9(18):e016441
pubmed: 32885738
BMC Infect Dis. 2008 Jun 25;8:86
pubmed: 18578883
J Immunol. 2010 May 15;184(10):5914-27
pubmed: 20404278
Infect Immun. 2020 Feb 20;88(3):
pubmed: 31818963
Vector Borne Zoonotic Dis. 2015 Apr;15(4):231-40
pubmed: 25674945
PLoS Negl Trop Dis. 2011 Aug;5(8):e1279
pubmed: 21858242

Auteurs

Isaclaudia Gomes de Azevedo-Quintanilha (I)

Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.

Mariana Macedo Campos (MM)

Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.

Ana Paula Teixeira Monteiro (AP)

Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.

Alessandra Dantas do Nascimento (A)

Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Instituto D'Or de Pesquisa e Ensino, Rio de Janeiro, Brazil.

Andrea Surrage Calheiros (AS)

Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.

Douglas Mathias Oliveira (DM)

Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.

Suelen Silva Gomes Dias (SSG)

Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.

Vinicius Cardoso Soares (VC)

Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.

Julia da Cunha Santos (JDC)

Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.

Isabel Tavares (I)

Instituto D'Or de Pesquisa e Ensino, Rio de Janeiro, Brazil.

Thiago Moreno Lopes Souza (TM)

Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Centro de Desenvolvimento Tecnológico em Saúde (CDTS) and National Institute for Science and Technology on Innovation on Diseases of Neglected Populations (INCT/IDNP), FIOCRUZ, Rio de Janeiro, Brazil.

Eugenio D Hottz (ED)

Laboratório de Imunotrombose, Departamento de Bioquimica, Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil.

Fernando A Bozza (FA)

Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Instituto D'Or de Pesquisa e Ensino, Rio de Janeiro, Brazil.

Patricia T Bozza (PT)

Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH